**MINUTES**

**CPIC CONFERENCE CALL**

DATE: December 3, 2020

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| FDA Citizen Petition – *DPYD* Testing | Dan Hertz presented on a recently submitted citizen petition to the FDA to add a requirement for *DPYD* testing prior to prescribing 5-fluorouracil and capecitabine on their FDA-approved drug labels: <https://beta.regulations.gov/document/FDA-2020-P-2213-0001>. The petition is open for public comment. It would be helpful for clinicians to add comments supporting the petition, including comments on the feasibility of adding testing to the workflow, and for testing company representatives to add comments about improvements in accuracy, access, and cost/reimbursement from expanding use. Slides will be included with the minutes. | Add supportive comments to the petition during FDA open comment period. |
| *CYP2D6*/antipsychotics | Jeff Bishop and Daniel Mueller presented on the evidence linking *CYP2D6* genetic variation with antipsychotic pharmacokinetics and clinical outcomes. Many were supportive of this guideline. Slides will be included with the minutes. | *CYP2D6*/antipsychotics is currently on CPIC’s list for a future guideline. https://cpicpgx.org/prioritization-of-cpic-guidelines/ |